| Literature DB >> 30231506 |
Ming-Yang Wang1, Jing-Wei Liang2, Kamara Mohamed Olounfeh3, Qi Sun4, Nan Zhao5, Fan-Hao Meng6.
Abstract
A combined in silico method was developed to predict potential protein targets that are involved in cardiotoxicity induced by aconitine alkaloids and to study the quantitative structure⁻toxicity relationship (QSTR) of these compounds. For the prediction research, a Protein-Protein Interaction (PPI) network was built from the extraction of useful information about protein interactions connected with aconitine cardiotoxicity, based on nearly a decade of literature and the STRING database. The software Cytoscape and the PharmMapper server were utilized to screen for essential proteins in the constructed network. The Calcium-Calmodulin-Dependent Protein Kinase II alpha (CAMK2A) and gamma (CAMK2G) were identified as potential targets. To obtain a deeper insight on the relationship between the toxicity and the structure of aconitine alkaloids, the present study utilized QSAR models built in Sybyl software that possess internal robustness and external high predictions. The molecular dynamics simulation carried out here have demonstrated that aconitine alkaloids possess binding stability for the receptor CAMK2G. In conclusion, this comprehensive method will serve as a tool for following a structural modification of the aconitine alkaloids and lead to a better insight into the cardiotoxicity induced by the compounds that have similar structures to its derivatives.Entities:
Keywords: aconitine; alkaloids; docking; network; quantitative structure–toxicity relationship (QSTR)
Mesh:
Substances:
Year: 2018 PMID: 30231506 PMCID: PMC6225272 DOI: 10.3390/molecules23092385
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1The whole framework of the comprehensive in silico method for screening potential targets and studying the quantitative structure–toxicity relationship (QSTR).
The partial least square (PLS) statistical parameters for the CoMFA and CoMSIA.
| PLS Statistical Parameters | CoMFA | CoMSIA |
|---|---|---|
| q2 a | 0.624 | 0.719 |
| r2 b | 0.966 | 0.901 |
| ONC c | 6 | 4 |
| SEE d | 0.043 | 0.116 |
| F e | 124.127 | 157.458 |
| rpred2 f | 0.903 | 0.894 |
| Fraction of Field contribution g | ||
| steric | 0.621 | 0.120 |
| Electrostatic | 0.379 | 0.204 |
| Hydrophobic | - | 0.327 |
| H-bond acceptor | - | 0.216 |
| H-bond donor | - | 0.133 |
a Cross-validated correlation coefficient; b Non-cross-validated correlation coefficient; c Optimum number of components; d Standard error of estimate; e F-test value; f The predictive r2 value; g Field: steric, electrostatic, hydrophobic, hydrogen-bond acceptor, and hydrogen-bond donor.
Figure 2Experimental versus predicted activity of the training and test sets based on the comparative molecular field analysis (CoMFA) model (A) and comparative molecular similarity index analysis (CoMSIA) model (B).
Figure 3Residuals vs. Leverage Williams plots of the aconitine Topomer CoMFA (A) and CoMSIA (B) models.
Proteins related to aconitine alkaloids induced cardiotoxicity extracted from 274 articles.
| Name | Classification | Frequency |
|---|---|---|
| RYR2 | Ryanodine receptor 2 | 19 |
| RYR1 | Ryanodine receptor 1 | 15 |
| GJA1 | Gap junction α-1 protein (connexin43) | 13 |
| SLC8A1 | Sodium/calcium exchanger 1 | 11 |
| ATP2A1 | Calcium transporting ATPase fast twitch 1 | 9 |
| KCNH2 | Potassium voltage-gated channel H2 | 7 |
| SCN3A | Sodium voltage-gated channel type 3, | 3 |
| SCN2A | Sodium voltage-gated channel type 2 | 3 |
| SCN8A | Sodium voltage-gated channel type 8 | 2 |
| SCN1A | Sodium voltage-gated channel type 1 | 2 |
| SCN4A | Sodium voltage-gated channel type 4 | 1 |
| KCNJ3 | Potassium inwardly-rectifying channel J3 | 1 |
Figure 4(A) The PPI network of proteins about cardiotoxicity induced by aconitine alkaloids. (B) The sub-network with essential protein generated from the Cytoscape and CytoNCA plugin.
Figure 5(A) Common targets of three aconitine alkaloids obtained from overlapping the PharmMapper results. (B) The potential target received from superimposing the PharmMapper and CytoNCA result.
Ranking results by experimental and predicted pLD50 and fit score.
| Compounds | Experimental pLD50 | Fit Score (2V7O) | Fit Score (2VZ6) |
|---|---|---|---|
| 6 | 1 | 3 | 3 |
| 20 | 2 | 1 | 12 |
| 12 | 3 | 4 | 9 |
| 1 | 4 | 2 | 4 |
| 11 | 5 | 7 | 2 |
| 14 | 6 | 8 | 13 |
| 16 | 7 | 5 | 6 |
| 7 | 8 | 17 | 15 |
| 8 | 9 | 10 | 11 |
| 27 | 10 | 23 | 17 |
| 13 | 11 | 12 | 19 |
| 15 | 12 | 11 | 5 |
| 32 | 13 | 18 | 18 |
| 5 | 14 | 22 | 8 |
| 33 | 15 | 13 | 29 |
| 21 | 16 | 15 | 1 |
| 25 | 17 | 9 | 20 |
| 22 | 18 | 25 | 25 |
| 17 | 19 | 20 | 16 |
| 28 | 20 | 24 | 30 |
| 9 | 21 | 16 | 32 |
| 29 | 22 | 32 | 14 |
| 2 | 23 | 30 | 24 |
| 30 | 24 | 31 | 26 |
| 18 | 25 | 21 | 27 |
| 10 | 26 | 26 | 21 |
| 23 | 27 | 29 | 31 |
| 31 | 28 | 33 | 7 |
| 26 | 29 | 14 | 23 |
| 4 | 30 | 28 | 33 |
| 3 | 31 | 6 | 10 |
| 19 | 32 | 27 | 28 |
| 24 | 33 | 19 | 22 |
| NDCG | 1 | 0.9122 | 0.8503 |
Figure 6CoMSIA and CoMFA contour maps around Compound 6. (A) The CoMFA steric contour map, (B) the CoMFA electrostatic contour map, (C) the CoMSIA hydrophobic field contour maps, (D) the CoMSIA hydrogen bond donor field, and (E) the CoMSIA hydrogen bond acceptor field.
Figure 7Sub-graphs of the PPI network of aconitine alkaloids induced cardiotoxicity analyzed using the ClusterONE plugin.
Figure 8(A) The interactions between the four compounds and amino acids are shown by the ligand interaction function in MOE software. (B) The mechanisms of the CaMKII activation state and inactivation state. (C) The dock result of Compound 20. Compound 20 docked into 2V7O, and the ATP-competitive pocket was painted green; the T287, T307, and T308 phosphorylation sites were painted green, orange, and yellow, respectively; the inhibitory helix was painted red.
Figure 9RMSD tendency of the ligand–receptor complex at different MD simulation times in the 5 ns MD simulation.
Figure 10Crucial requirement of cardiotoxicity mechanism was obtained from the ligand-based 3D-QSTR and structure-based molecular docking study.
Structure of Aconitine alkaloids with toxic activity.
| No. | CAS. NO | Substituent in R1 to R13 | pLD50 |
|---|---|---|---|
| 1 | 302-27-2 | methoxymethyl-hydroxy-methoxy-methoxy-H-acetoxyl-hydroxy-methoxy-benzoxy-H-hydroxy-H-ethyl | 4.92 |
| 2* | 545-56-2 | methoxymethyl-H-hydroxy-methoxy-hydroxy-hydroxy-H-methoxy-hydroxy-H-H-H-ethyl | 1.96 |
| 3 | 127-29-7 | methoxymethyl-hydroxy-methoxy-methoxy-H-acetoxyl-H-methoxy-methyl 2,3-dimethoxybenzoate-H-hydroxy-H-ethyl | 1.44 |
| 4 | 509-18-2 | methoxymethyl-H-hydroxy-methoxy-hydroxy-hydroxy-H-methoxy-methoxy-H-H-H-ethyl | 1.76 |
| 5* | 466-24-0 | methoxymethyl-hydroxy-methoxy-methoxy-H-hydroxy-hydroxy-methoxy-benzoxy-H-hydroxy-H-ethyl | 3.00 |
| 6 | 2752-64-9 | methoxymethyl-hydroxy-methoxy-methoxy-H-acetoxyl-hydroxy-methoxy-benzoxy-H-hydroxy-H-methy | 5.00 |
| 7 | 4491-19-4 | methoxymethyl-hydroxy-methoxy-methoxy-H-acetoxyl-H-methoxy-benzoxy-H-hydroxy-H-ethyl | 4.33 |
| 8* | 6900-87-4 | methoxymethyl-H-methoxy-methoxy-H-acetoxyl-hydroxy-methoxy-benzoxy-H-hydroxy-H-methy | 4.33 |
| 9 | 1356-52-1 | H-H-methoxy-H-H-hydroxy-H-methoxy-benzoxy-H-H-hydroxy-H-ethyl | 2.55 |
| 10 | 6836-11-9 | methy-H-methoxy-acetoxyl-dioxolane-H-H-methoxy-methoxy-H-H-hydroxy-ethyl | 1.88 |
| 11 | 8006-38-0 | methoxymethyl-hydroxy-methoxy-methoxy-H-acetoxyl-hydroxy-methoxy-benzoxy-H-hydroxy-H-ethyl | 4.78 |
| 12* | 20501-56-8 | methoxymethyl-H-methoxy-H-H-hydroxy-H-methoxy-hydroxy-H-H-H-ethyl | 4.94 |
| 13 | 21019-30-7 | 2-(3-methyl-2,5-dioxopyrrolidin-1-yl)benzoate ethyl-H-methoxy-methoxy-hydroxy-hydroxy-H-methoxy-methoxy-H-H-H-ethyl | 3.52 |
| 14 | 41849-35-8 | methoxymethyl-hydroxy-methoxy-methoxy-H-acetoxyl-hydroxy-methoxy-benzoxy-H-hydroxy-hydroxy-ethyl | 4.66 |
| 15 | 26000-16-8 | 2-(3-methyl-2,5-dioxopyrrolidin-1-yl)benzoate ethyl-H-methoxy-methoxy-a-H-H-methoxy-methoxy-H-H-H-ethyl | 3.3 |
| 16 | 77181-26-1 | methoxymethyl-acetoxyl-methoxy-methoxy-H-acetoxyl-hydroxy-methoxy-benzoxy-H-hydroxy-H-ethyl | 4.4 |
| 17 | 71402-60-3 | methoxymethyl-hydroxy-methoxy-methoxy-H-hydroxy-hydroxy-methoxy-benzoxy-H-hydroxy-H-trimethylethanaminium | 2.59 |
| 18 | 67806-02-4 | methoxymethyl-acetoxyl-methoxy-methoxy-H-acetoxyl-acetoxyl-methoxy-benzoxy-H-acetoxyl-H-ethyl | 1.9 |
| 19 | 85031-25-0 | methoxymethyl-acetoxyl-methoxy-methoxy-H-acetoxyl-acetoxyl-methoxy-acetoxyl-H-acetoxyl-H-ethyl | 1.17 |
| 20 | 71425-64-4 | methoxymethyl-hydroxy-methoxy-methoxy-H-acetoxyl-hydroxy-methoxy-benzoxy-H-hydroxy-H-trimethylethanaminium | 4.95 |
| 21* | 63238-67-5 | methoxymethyl-hydroxy-methoxy-methoxy-H-hydroxy-hydroxy-methoxy-benzoxy-H-hydroxy-H-methy | 2.68 |
| 22 | 71402-61-4 | methoxymethyl-hydroxy-methoxy-methoxy-H-hydroxy-hydroxy-methoxy-benzoxy-hydroxy-H-H-trimethylethanaminium | 2.62 |
| 23 | 38146-89-3 | methoxymethyl-hydroxy-methoxy-methoxy-H-hydroxy-H-methoxy-hydroxy-H-hydroxy-H-ethyl | 1.85 |
| 24 | 82144-73-8 | methoxymethyl-acetoxyl-methoxy-methoxy-H-acetoxyl-H-methoxy-benzoxy-H-hydroxy-H-ethyl | 0.84 |
| 25 | 82144-74-9 | methoxymethyl-acetoxyl-methoxy-methoxy-H-acetoxyl-H-methoxy-benzoxy-H-acetoxyl-H-ethyl | 2.66 |
| 26 | 38146-91-7 | methoxymethyl-acetoxyl-methoxy-methoxy-H-acetoxyl-H-methoxy-acetoxyl-H-acetoxyl-H-ethyl | 1.82 |
| 27* | 71402-59-0 | methoxymethyl-H-methoxy-methoxy-H-acetoxyl-hydroxy-methoxy-benzoxy-H-hydroxy-H-ethyl | 4.27 |
| 28 | 71402-62-5 | methoxymethyl-H-hydroxy-methoxy-H-hydroxy-hydroxy-methoxy-benzoxy-H-hydroxy-H-methy | 2.59 |
| 29 | 39089-30-0 | methy-H-hydroxy-H-H-hydroxy-H-methoxy-hydroxy-H-H-H-ethyl | 2.29 |
| 30 | 58111-33-4 | methoxymethyl-H-hydroxy-methoxy-hydroxy-hydroxy-H-methoxy-H-methoxy-H-H-trimethylethanaminium | 1.93 |
| 31* | 23943-93-3 | hydroxy-H-methoxy-hydroxy-H-hydroxy-H-methoxy-methoxy-H-H-H-ethyl | 1.85 |
| 32 | 32854-75-4 | 2-acetamidobenzoate ethyl-H-methoxy-H-H-hydroxy-H-methoxy-methoxy-hydroxy-H-H-ethyl | 3.16 |
| 33 | 138729-51-8 | 2-acetamidobenzoate ethyl-H-methoxy-H-H-acetoxyl-H-methoxy-methoxy-acetoxyl-H-H-ethyl | 2.84 |
* Test set compound.